Non categorizzato

Non categorizzato

+
31.10.2023
A word with Andrea Taborelli – Interview with Chimica Oggi – Chemistry Today
Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons. 
+
12.10.2023
CPHI October 24-26 Barcelona: IBSA presents cutting-edge technologies to drive pharmaceutical innovation.
As a global pharmaceutical company, IBSA is driven by a distinct vision of care, which starts at the Swiss headquarters and extends globally through continued growth in Europe, Asia, and North America. IBSA’s technologies are aimed at creating more advanced treatment systems to provide healthcare professionals with innovative, effective and reliable therapeutic solutions that improve patients’ quality of life. The product portfolio
Read more
+
23.05.2023
IBSA at CPHI Japan: increase brand awareness and expand presence in the Asian countries
24 MAY 2023 From the 19th to the 21st of April 2023, the CPHI Japan fair was held in Tokyo. An ideal business event for international pharmaceutical professionals to grow their business in the rapidly changing Asian market. IBSA took part in the fair, thus having the opportunity to present its innovations in the pharmaceutical field, presenting new products and
Read more
+
27.03.2023
CPHI April 19-21 TOKYO: IBSA returns to Japan after the pandemic.
IBSA operates in more than 90 countries and 5 continents with 17 subsidiaries in Europe, China and the USA, and employs over 2,000 collaborators distributed among our headquarters, subsidiaries and manufacturing plants. The Group boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.
Read more
+
14.03.2023
DELIVERING INNOVATIVE SOLUTIONS FOR THE NUTRACEUTICAL MARKET
IBSA was established in Lugano in 1945 and started developing its special identity in 1985 when it was acquired by the current ownership, which adopted a new strategy focused on the acquisition of technological resources and launched a development programme aimed at consolidating its global expansion and developing company assets. Today IBSA is present in over 90 countries in 5
Read more
+
02.11.2022
IBSA: STRATEGIC LICENSING AND CDMO PROJECTS FOR THE PHARMACEUTICAL MARKET
IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.
+
11.10.2022
Interview with Chimica Oggi – Chemistry Today
Andrea Toborelli, Business Development and Licensing Manager at IBSA, was interview by Nutra Horizons. 
+
09.09.2022
IBSA, the 3 generations of hyaluronic acid for infiltrative therapy
IBSA is one of the world leaders in the production of hyaluronic acid by biofermentation.
+
03.08.2022
IBSA Farmaceutici: synonymous with innovation
The treatment of pain has been present throughout the history of medicine. This is confirmed by sources dating back 5,000 years, in which reference is made to natural analgesics. This calls for reflection on the fact that human beings have always turned to medicine for solutions for all types of physical pain. This search has never stopped and continues today.
We’re looking for partners and international distributors for our products.
GET IN TOUCH WITH US
logo-footer

Headquarter

 

Via del Piano 29,
6926 Collina d’Oro,
Switzerland
Tel. +41 58 360 10 00

 

 

 

Follow us